Will Contrast-Induced Nephropathy Kill You?
Contrast-induced nephropathy (CIN) is a form of acute renal failure precipitated by exposure to these radiocontrast agents. In other words, it is hospital-acquired. The question is: will it kill you?
feature2
Wound Management Sells Non-Core Subsidiary; Intends to Focus on CellerateRX and Medical Device Business
In total, over $500,000 in debt was removed from the balance sheet of Wound Management.
TONIX Pharmaceuticals Completes $4.3 Million Private Placement Funding
The company received net proceeds of approximately $1.9 million in the offering and converted an additional $1.9 million in previously convertible debentures as part of the offering.
This Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
BREAKING NEWS: Advaxis Reports Preliminary Safety and Survival Data from a Phase 2 Trial in Recurrent/Refractory Cervical Cancer
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies.
S.E.A. Medical Secures $3 Million in Series B Financing from JK&B Capital
Healthtech company makes strides towards developing medical devices designed to catch life-threatening IV drug errors before they harm patients
Provectus Receives Guidance From FDA On Pathway to Approval for Phase 3 Trial of PV-10 For Metastatic Melanoma
Dr. Craig Dees talks candidly in a live audio interview about the company’s developments.
This Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Miracor Aims to Cure More Than 350K Broken Hearts Per Year with New PCI Intervention System
Three million patients are treated for restricted coronary blood flow every year.
Biocept, Inc. Making Advances in Circulating Tumor Cell Research for Cancers
To date, most CTC capture and detection technologies have not been able to recognize the cytokeratin negative (CK‐) CTCs. Biocept’s Cell Enrichment and Extraction (CEETM) platform allows for the capture of these CK- cells as well as CK+ CTC phenotypes